Literature DB >> 17442375

Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the bmi-1 and ras oncogenes in disease progression.

Chunlei Zhang1, Albena Toulev, Jivko Kamarashev, Jian-Zhong Qin, Reinhard Dummer, Udo Döbbeling.   

Abstract

In examining the expression of oncogenes and tumor suppressor genes in mycosis fungoides and Sézary syndrome, we found the cell cycle-regulating protein p16 to be absent in T cells. Immunohistochemical staining with p16-specific antibodies showed that the number of p16-expressing cells in cutaneous lesions decreases in late stages. The repression of p16 was not attributable to deletion or methylation of this gene; however, the Bmi-1 oncogene, a known suppressor of p16, was present in mycosis fungoides and Sézary syndrome cell lines and skin lesions. The absence of p16 correlated with the phosphorylation of the retinoblastoma protein on cyclin D/CDK4- or cyclin D/CDK6-specific sites. Ki-ras, which stimulates phosphorylation of retinoblastoma via cyclin-dependent kinases, was found in all tested cutaneous T-cell lymphoma samples; and its expression generally was stronger in advanced stages. Thus, cutaneous T-cell lymphoma cells show changes in oncogene and tumor suppressor gene expression that increase proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442375     DOI: 10.1016/j.humpath.2006.10.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Authors:  Michael K Kiessling; Patrick A Oberholzer; Chandrani Mondal; Maria B Karpova; Marie C Zipser; William M Lin; Michael Girardi; Laura E Macconaill; Sarah M Kehoe; Charlie Hatton; Lars E French; Levi A Garraway; Gernot Polier; Dorothee Süss; Claus-Detlev Klemke; Peter H Krammer; Karsten Gülow; Reinhard Dummer
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

Review 2.  Methotrexate and Pralatrexate.

Authors:  Gary S Wood; Jianqiang Wu
Journal:  Dermatol Clin       Date:  2015-08-01       Impact factor: 3.478

Review 3.  Cancer stem cells: potential target for bioactive food components.

Authors:  Young S Kim; William Farrar; Nancy H Colburn; John A Milner
Journal:  J Nutr Biochem       Date:  2012-07       Impact factor: 6.048

4.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

5.  MicroRNAs and their signaling pathway in mycosis fungoides.

Authors:  Zhiyuan Sun; Xiaona Yao; Xing Ding; Xun Li; Xuewen Tian
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

6.  MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.

Authors:  A Kitadate; S Ikeda; K Teshima; M Ito; I Toyota; N Hasunuma; N Takahashi; T Miyagaki; M Sugaya; H Tagawa
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

7.  BMI-1 autoantibody as a new potential biomarker for cervical carcinoma.

Authors:  Yong-Qing Tong; Bei Liu; Hong-Yun Zheng; Yu-Juan He; Jian Gu; Feng Li; Yan Li
Journal:  PLoS One       Date:  2011-11-21       Impact factor: 3.240

Review 8.  BMI1: A Biomarker of Hematologic Malignancies.

Authors:  Anagh A Sahasrabuddhe
Journal:  Biomark Cancer       Date:  2016-05-05

9.  Altered expression of Bcl-2, c-Myc, H-Ras, K-Ras, and N-Ras does not influence the course of mycosis fungoides.

Authors:  Joanna Maj; Alina Jankowska-Konsur; Ewa Plomer-Niezgoda; Anna Sadakierska-Chudy; Adam Reich
Journal:  Arch Med Sci       Date:  2013-11-05       Impact factor: 3.318

10.  p16INK4a Expression in Porokeratosis.

Authors:  Miki Uryu; Masutaka Furue
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.